Drugs / STI-3031
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05653661 | Jul 2024 | melanoma, metastatic malignant neoplasm | Mayo Clinic | Withdrawn | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT03999658 | Mar 2023 → Jan 2024 | biliary tract cancer, diffuse large B-cell lymphoma, extranodal nasal NK/T cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04809012 | Jun 2021 → Jun 2024 | refractory malignant neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-3031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809012 ↗ |
| Known as | danburstotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05653661 ↗ |
| Route | Intravenous | “Intravenous STI-3031 (anti-PD-L1 antibody)” NCT03999658 ↗ |